Studies of Drug Utilization

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 377-401

  Lee, David ^a   Bergman, Ulf ^b,c  

^a MANAGEMENT SCIENCES FOR HEALTH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adherence indicator; Defined daily dose; Drug use indicator; Drug utilization review; Drug utilization study; Medicine use survey; Pharmaceutical database; Prescribed daily dose; Prescription database; Rational drug use

Indexed keywords

EID: 84888733920     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch24     Document Type: Chapter

References (180)

1. WHO Expert Committee. The Selection of Essential Drugs. Technical Report Series No. 615. Geneva: World Health Organization, 1977.
2. Lunde PKM, Andrew M, Baksaas I. Drug utilization -an instrument in drug research. In: Kewitz H, Roots I, Voight K, eds. Epidemiological Concepts in Clinical Pharmacology. Berlin: Springer -Verlag, 1987, pp. 57-72.
3. Brodie DC. Drug Utilization and Drug Utilization Review and Control. NCHS -RD-70-8. Rockville: Department of Health, Education, and Welfare, National Center for Health Services Research and Development, Health Services and Mental Health Administration, 1970.
4. Conley BE. Social and Economic Aspects of Drug Utilization Research. Hamilton: Drug Intelligence Publications, Inc., 1976.
5. Baksaas I, Lunde PKM. Drug utilization: Pharmacokinetics in the community. Trends Pharmacol Sci 1981; 2: 5-7.
6. Laporte JR, Tognoni G, eds. Principios de Epidemiolog í a del Medicamento, 2nd edn. Barcelona: Ediciones Científicas y T écnicas, 1993.
7. Lunde PKM, Baksaas I. Epidemiology of drug utilization-basic concepts and methodology. Acta Med Scand Suppl 1988; 721: 7-11.
8. Stolar MH. Drug use review: Operational definitions. Am J Hosp Pharm 1978; 35: 76-8.
9. Lee PR. America is an overmedicated society. In: Lasagna L, ed. Controversies in Therapeutics. Philadelphia: W. B. Saunders Company, 1980, pp. 4-15.
10. Scheckler NE, Bennet JV. Antibiotic usage in seven community hospitals. JAMA 1970; 213: 264-7.
11. Roberts WA, Visconti AJ. The rational and irrational use of systemic antimicrobial drugs. Am J Hosp Pharm 1972; 29: 828-34.
12. Castle M, Wilfert CM, Cate TR, Osterhout S. Antibiotic use at Duke University Medical Center. JAMA 1977; 237: 2819-22.
13. Perry TL, Guyatt GH. Antimicrobial drug use in three Canadian hospitals. CMAJ 1977; 116: 253-6.
14. Achong MR, Hauser BA, Krusky JL. Rational and irrational use of antibiotics in a Canadian teaching hospital. CMAJ 1977; 116: 256-9.
15. Shapiro M, Townsend TR, Rosner B, Kass EH. Use of antimicrobial drugs in general hospitals. II. Analysis of patterns of use. J Infect Dis 1979; 139: 698-706.
16. Townsend TR, Shapiro M, Rosner B, Kass EH. Use of antimicrobial drugs in general hospitals. IV. Infants and children. Pediatrics 1979; 64: 573-8.
17. Schollenberg E, Albritton WL. Antibiotic misuse in a pediatric teaching hospital. CMAJ 1980; 122: 49-52.
18. Naqvi SH, Dunkle LM, Timmerman KJ, Reichley RM, Stanley DL, O'Connor D. Antibiotic usage in a pediatric medical center. JAMA 1980; 242: 1981-4.
19. Laporte JR, Porta M, Capellá D. Drug utilization studies: A tool for determining the effectiveness of drug use. Br J Clin Pharmacol 1983; 16: 301-4.
20. Garattini S, Garattini L. Pharmaceutical prescriptions in four European countries. Lancet 1993; 342: 1191-2.
21. Casado Zuriguel I. Intervención para mejorar la calidad de prescripci ón de antibi óticos en una area básica de salud. Aten Primaria 1993; 11: 37-9.
22. Mata Cases M, Avellana Revuelta E, Davins Miralles J, Calvet Junoy S, Hortelano Garc ía MA, Martín López A. Mejora continua de la calidad de la pre-scripción cr ónica en un centro de atenci ón primaria: seguimiento de 5 a ños. Aten Primaria 1994; 13: 172-6.
23. Heineck I, Schenkel EP, Vidal X. Medicamentos de venta libre en el Brasil. Rev Panam Salud P ú blica 1998; 3: 385-91.
24. Meza Cornejo EA. Valor Terap é utico de los Medicamentos m á s Vendidos en ele Per ú. AIS LAC Serie Investigaciones y Monograf ías No. 31/2010. Lima, Per ú: Acción Internacional para la Salud, 2010.
25. Wettermark B, Pehrsson A, Jinnerot D, Bergman U. Drug utilization 90% profiles -a useful tool for quality assessment of prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 2003; 12: 499-510.
26. Teichert M, van der Aalst A, de Wit H, Stroo M, De Smet PAGM. How useful are prescribing indicators based on the DU90% method to distinguish the quality of prescribing between pharmacotherapy audit meetings with different levels of functioning. Eur J Clin Pharmacol 2007; 63: 1171-77.
27. Bergman U, Andersen M, Vaccheri A, Bjerrum L, Wettermark B, Montanaro N. Deviations from evidence-based prescribing of non -steroidal anti -inflammatory drugs in three European regions. Eur J Clin Pharmacol 2000; 56: 269-72.
28. Vlahovic-Palcevski V, Wettermark B, Bergman U. Quality of non -steroidal anti -inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). Eur J Clin Pharmacol 2002; 58: 209-14.
29. Vaccheri A, Bjerrum L, Resi D, Bergman U, Montanaro N. Antibiotic prescribing in general practice: striking differences between Italy (Ravenna) and Denmark (Funen). J Antimicrob Chemotherapy 2002; 50: 989-97.
30. Krivoy N, El-Ahal WA, Bar -Lavie Y, Haddad S. Antibiotic prescription and cost patterns in a general intensive care unit. Pharmacy Practice 2007; 5: 67-73.
31. Wettermark B, Pehrsson Å, Juhasz-Haverinen M, Veg A, Edlert M, Tornwall -Bergendahl, et al. Quality in Primary Care 2009; 17: 179-89.
32. Todd M. Drug use evaluation. In: Brown TR, ed. Handbook of Institutional Pharmacy Practice, 3rd edn. Bethesda, MD: American Society of Hospital Pharmacists, 1992, pp. 261-71.
33. Sjöqvist F, Agenäs I, eds. Drug utilization studies: Implications for medical care. Acta Med Scand 1984; Suppl 683.
34. Baksaas I, Lunde PKM. National drug policies: The need for drug utilization studies. Trends Pharmacol Sci 1986; 7: 331-4.
35. Westerholm B. Therapeutic auditing at the national and international level. Br J Clin Pharmacol 1986; 22: 55S-59S.
36. Melmon KL. Preventable drug reactions: Causes and cures. N Engl J Med 1971; 284: 1361-3.
37. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out -patients: a systematic review and meta -analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83.
38. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Health Care 2003; 15 (Suppl 1): i49-59.
39. Davidsen F, Haghfelt T, Gram LF, Brøsen K. Adverse drug reactions and drug non -compliance as primary causes of admission to a cardiology department. Eur J Clin Pharmacol 1988; 34: 83-6.
40. Bates DW. Medication errors: how common are they and what can be done to prevent them? Drug Saf 1996; 15: 303-10.
41. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore: Johns Hopkins University Press, 1979.
42. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs -do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31.
43. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid -lowering medications: a cross -national study. JAMA 1998; 279: 1458-62.
44. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid -lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 463-71.
45. Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992; 85: 444-8.
46. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta -blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-21.
47. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997: 157: 441-5.
48. Antani MR, Beyth RJ, Covinsky KE, Anderson PA, Miller DG, Cebul RD, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11: 713-20.
49. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156: 2311-6.
50. Mendelson G, Aronow WS. Underutilization of measurement of serum low -density lipoprotein cholesterol levels and of lipid -lowering therapy in older patients with manifest atherosclerotic disease. J Am Geriatr Soc 1998; 46: 1128-31.
51. Aronow S. Underutilization of lipid -lowering drugs in older persons with prior myocardial infarction and a serum low -density lipoprotein cholesterol >125mg/dl. Am J Cardiol 1998; 82: 668-9, A6, A8.
52. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbasi C, Guadagnoli E, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med 1996; 156: 799-805.
53. Krumholtz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 1995; 92: 2841-7.
54. O'Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 1999; 281: 627-33.
55. Haider BA, Saeed MA, Bhutta ZA. Short-course versus long -course antibiotic therapy for non -severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev 2008; 2: CD005976.
56. Strom BL, Melmon KL, Miettinen OS. Postmarketing studies of drug efficacy. Arch Intern Med 1985; 145: 1791-4.
57. Lasagna L. A plea for the naturalistic study of medicines. Eur J Clin Pharmacol 1974; 7: 153-4.
58. Rucker TD. Data, sources, and limitations. JAMA 1974; 230: 888-90.
59. Anonymous. Consumption of Drugs: Report on a Symposium. Euro 3102. Copenhagen: WHO Regional Office for Europe, 1970.
60. Bergman U. Pharmacoepidemiology-from description to quality assessment. A Swedish perspective. Norwegian J Epidemiology 2001; 11: 31-6.
61. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Stolley PD, et al. Using a claims database to investigate drug -induced Stevens -Johnson syndrome. Stat Med 1991; 10: 565-76.
62. Rucker TD. Drug utilization review: Guidelines for program development. In: Alloza JL, ed. Clinical and Social Pharmacology. Postmarketing Period. Aulendorf: Cantor, 1985, p. 57.
63. Bergman U, Grímsson A, Wahba AHW, Westerholm B, eds. Studies in drug utilization. European series No. 8. Copenhagen: WHO Regional Office for Europe; 1979. Anonymous. Panel III. Intervention: the use of drug utilization review outcomes. Clin Pharmacol Ther 1991; 50: 633-5.
64. Dukes MNG, ed. Drug Utilization Studies: Methods and Uses. European Series, No. 45. Copenhagen: World Health Organization, Regional Office for Europe, 1993.
65. Bergman U, Elmes P, Halse M, Halvorsen T, Hood H, Lunde PK, et al. The measurement of drug consumption: drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 1975; 8: 83-9.
66. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-3.
67. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid -lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilio Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997: 53: 185-9.
68. WHO Drug Utilization Research Group (DURG). Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 1985; 29: 1-8.
69. WHO Drug Utilization Research Group (DURG). Therapeutic traditions in Northern Ireland, Norway and Sweden. I. Diabetes. Eur J Clin Pharmacol 1986; 30: 513-9.
70. WHO Drug Utilization Research Group (DURG). Therapeutic traditions in Northern Ireland, Norway and Sweden. II. Hypertension. Eur J Clin Pharmacol 1986; 30: 521-5.
71. Groop P-H, Klaukka T, Reunanen A, Bergman U, Borch-Johnsen K, Damsgaard E-M, et al. Diabetesl ä kemedel i Norden. Analys av orsaker till variationen i f ö rbrukningen. [Antidiabetic drugs in the Nordic countries. Reasons for variation in their use.] Social Insurance Publication ML 105. Helsinki: Social Insurance Institution, 1991.
72. Stålhammar J, Bergman U, Boman K, Dahlen M. Metabolic control in diabetic subjects in three Swedish areas with high, medium, and low sales of antidiabetic drugs. Diabetes Care 1991; 14: 12-9.
73. Baum C, Kennedy DL, Forbes MB, Jones JK. Drug use and expenditures in 1982. JAMA 1985; 253: 382-6.
74. Stolley PD, Lasagna L. Prescribing patterns of physicians. J Chronic Dis 1969; 22: 395-405.
75. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337-44.
76. Kelly JP, Kaufman DW, Kelley KE, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med 2005; 165: 281-6.
77. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Cough and cold medication use by U.S. children, 1999-2006: Results from the Slone Survey. Pediatrics 2008; 122: 323-9.
78. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Pseudoephedrine use among U.S. children 1999 - 2006: Results from the Slone Survey. Pediatrics 2008; 122: 1299-304.
79. Hemminki E. Review of literature on the factors affecting drug prescribing. Soc Sci Med 1975; 9: 111-15
80. Christensen DB, Bush PJ. Drug prescribing: Patterns, problems and proposals. Soc Sci Med 1981; 15: 343-55.
81. Soumerai SB,Avorn J. Efficacy and cost -containment in hospital pharmacotherapy: State of the art and future directions. Milbank Mem Fund Quart 1984; 62: 447-74.
82. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q 1989; 67: 268-317.
83. Anderson GM, Lexchin J. Strategies for improving prescribing practice. CMAJ 1996; 154: 1013-7.
84. Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2000; 2: CD000172.
85. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-22.
86. Gómez LA, Lobato CI. Evolución de las bases de datos de medicamentos del Ministerio de Sanidad y Consumo. Inf Ter Seg Soc 1987; 11: 229.
87. Avorn J, Soumerai SB. Use of computer -based Medicaid drug data to analyze and correct inappropriate medication use. J Med Syst 1982; 6: 377-8.
88. Boëthius G, Wiman F. Recording of drug prescriptions in the county of J ämtland, Sweden. I. Methodological aspects. Eur J Clin Pharmacol 1977; 12: 31-5.
89. Henriksson S, Boëthius G, Håkansson J, Isacsson G. Indications for and outcome of antidepressant medication in a general population: a prescription database and medical record study, in J ämtland county, Sweden, 1995. Acta Psychiatr Scand 2003; 108: 427-31.
90. Hallas J. Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol Drug Saf 2001; 10: 619-23.
91. Rosholm J-U, Gram LF, Isacsson G, Hallas J, Bergman U. Changes in the pattern of antidepressants use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 1997; 52: 205-9.
92. Gaist D, Hallas J, Hansen N-CG, Gram LF. Are young adults with asthma treated sufficiently with inhaled steroids? A population -based study of prescription data from 1991 and 1994. Br J Clin Pharmacol 1996; 41: 2885-9.
93. Gaist D, Tsiropoulos I, Sindrup SH, Hallas J, Rasmussen BK, Kagstrup J, et al. Inappropriate use of sumatriptan: population based register and interview study. Br Med J 1998; 316: 1352-3.
94. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sorensen HT. Major hemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 4997-503.
95. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J, Bergman U. Low use of long -term hormone replacement therapy in Denmark: a 5 -year population-based survey. Br J Clin Pharmacol 1999; 47: 323-8.
96. Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997; 8: 666-70.
97. Donnan PT, Steinke DT, Newton RW, Morris AD; DARTS/MEMO Collaboration. Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population -based study. Diabet Med 2002; 19: 606-10.
98. Bromley SE, de Vries CS, Farmer RD. Utilisation of hormone replacement therapy in the United Kingdom: a descriptive study using the general practice research database. BJOG 2004; 111: 369-76.
99. Nash D. National drug and therapeutic index. PT 2002; 27: 530.
100. Bingefors K. Computerised data bases on prescription drug use and health care in the community of Tierp, Sweden: experiences and challenges from a study of antidepressant -treated patients. Norwegian J Epidemiol 2001; 11: 23-9.
101. Isacson D, Ståhlhammar J. Prescription drug use among diabetics -a population study. J Chronic Dis 1987; 40: 651-60.
102. Ståhlhammar J, Berne C, Svärdsudd K. Do guidelines matter? A population -based study of diabetes use during 20 years. Scand J Prim Health Care 2001; 19: 163-9.
103. Isacson D, Carsjö K, Bergman U, Blackburn JL. Long-term use, mortality and migration among benzodiazepine users in a Swedish community: an eight year follow -up. J Clin Epidemiol 1992; 45: 429-36.
104. Lundberg L, Isacson D. The impact of over -thecounter availability of nasal sprays on sales, prescribing, and physician visits. Scand J Prim Health Care 1999; 17: 41-5.
105. Wettermark B, Hammar N, Fored CM, Leimanis A, Olausson PO, Bergman U, et al. The new Swedish Prescribed Drug Register -opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology Drug Saf 2007; 16: 726-35.
106. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic Countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2009; 106: 86-94.
107. Sturkenboom MCJM, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42 (Suppl 3): iii23-iii31.
108. Pont LG, Sturkenboom MC, van Gilst WH, Denig P, Haaijer -Ruskamp FM. Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000. Pharmacoepidemiol Drug Saf 2003; 12: 327-34.
109. Blackburn JL. The use of automated databases in North America. In: Crommelin DJA, Midha KK, eds. Topics in Pharmaceutical Sciences 1991: Proceedings of the 51st International Congress of Pharmaceutical Sciences of F.I.P., 1991 Sep 1 -6, Washington D.C., USA. Stuttgart: Medpharm Scientific Publishers, 1992, pp. 405-13.
110. Strom BL, Carson JL, Morse ML, LeRoy AA. The Computerized On -line Medicaid Pharmaceutical Analysis and Surveillance System: a new resource for postmarketing drug surveillance. Clin Pharmacol Ther 1985; 38: 359-64.
111. Strom BL, Morse ML. Use of computerized data bases to survey drug utilization in relation to diagnoses. Acta Med Scand Suppl 1988; 721: 13-20.
112. Anonymous. Patterns of Medication Use in the United States 2006. A Report from the Slone Survey. Slone Epidemiology Center. Boston, MA: Boston University. http://www.bu.edu/slone/SloneSurvey/ AnnualRpt/SloneSurveyWebReport2006.pdf(accessed Aug 2011).
113. Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1997 -2000. Int J Clin Pharmacol Ther 2003; 41: 207-12.
114. Pelaez-Ballestas I, Hernandez-Garduno A, Arredondo-Garcia JL, Viramontes -Madrid JL, Aguilar -Chiu. Use of antibiotics in upper respiratory infections on patients under 16 years old in private ambulatory medicine. Salud Publica Mex 2003; 45: 159-64.
115. Kahan E, Kahan NR, Chinitz DP. Urinary tract infection in women -physician's preferences for treatment and adherence to guidelines: a national drug utilization study in a managed care setting. Eur J Clin Pharmacol 2003; 59: 663-8.
116. World Health Organization. How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators. WHO/DAP/93.1.Geneva:World Health Organization, 1993.
117. Trap B, Hansen EH, Hogerzeil HV. Prescription habits of dispensing and non -dispensing doctors in Zimbabwe. Health Policy Plan 2002; 17: 288-95.
118. Sunartono. From research to action: the Gunungkidul experience. Essential Drugs Monitor 1995; 2: 21-2.
119. Santoso B, Suryawati S, Prawitasari JE, Ross-Degnan D. Small group intervention vs formal seminar for improving appropriate drug use. Soc Sci Med 1996; 42: 1163-8.
120. Ofori-Adjei D, Arhinful DK. Effect of training on the clinical management of malaria by medical assistants in Ghana. Soc Sci Med 1996; 42: 1169-76.
121. Hadiyono JE, Suryawati S, Danu SS, Sunartono, Santoso B. Interactional group discussion: results of a controlled trial using a behavioral intervention to reduce the use of injections in public health facilities. Soc Sci Med 1996; 42: 1177-83.
122. World Health Organization. Medicines use in Primary Care in Developing and Transitional Countries: Fact Book Summarizing Results from Studies Reported Between 1990 and 2006. WHO/EMP/MAR/2009.3. Geneva, Switzerland: World Health Organization, 2009.
123. Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadeg H, Gitau L, Ntaganira J, et al. Measuring adherence to antiretroviral treatment in resource -poor settings: the clinical validity of key indicators. BMC Health Services Research 2010; 10: 42.
124. Chalker JC, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadeg H, et al. Measuring adherence to antiretroviral treatment in resource -poor settings: the feasibility of collecting routine data for key indicators. BMC Health Services Research 2010; 10: 43.
125. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2010. Oslo, 2009.
126. Bergman U, Boman G, Wiholm BE. Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J 1978; 2: 464-6.
127. Lee D, Chaves Matamoros A, Mora Duarte J. Changing patterns of antibiotic utilization patterns in Costa Rica. APUA Newslett 1991; 9: 7.
128. Schussel K, Schulz M. Prescribing of COX -2 inhibitors in Germany after safety warnings and market withdrawals. Pharmazie 2006; 61: 878-86.
129. Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997 - 2007. Rev Panam Salud Publica 2010; 27: 219-25.
130. Bronzwaer SLAM, Cars O, Bucholz U, Mölstad S, Goettsch W, Veldhuijzen IK, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-82.
131. Gulbinovic J, Myrback K-E, Bytautiene J, Wettermark B, Struwe J, Bergman U. Marked differences in antibiotic use and resistance between university hospitals in Vilnius, Lithuania, and Huddinge, Sweden. Microb Drug Resist 2001; 7: 383-8.
132. Mölstad S, Ernell M, Hanberger H, Melander E, Norman C, Skoog G, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10 -year follow-up of the Swedish Strama programme. Lancet Infect Dis 2008; 8: 125-32.
133. Nappo S, Carlini EA. Preliminary finding: consumption of benzodiazepines in Brazil during the years 1988 and 1989. Drug Alcohol Depend 1993; 33: 11-7.
134. Chen L,Wang Y, Jin Y. [Study on drug use in elderly outpatients in Beijing]. Zhonghua Liu Xing Bing Xue Za Zhi 2001; 22: 414-7.
135. Truter I, Wiseman K, Kotze TT. The defined daily dose as a measure of drug consumption in South Africa. A preliminary study. S Afr Med J 1996; 86: 675-9.
136. Su TP, Chen TJ, Hwang SJ, Chou LF, Fan AP, Chen YC. Utilization of psychotropic drugs in Taiwan: an overview of outpatient sector in 2000. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65: 378-91.
137. Vlahovic-Palevski V, Palcevski G, Mavric Z, Francetic I. Factors influencing antimicrobial utilization at a university hospital during a period of 11 years. Int J Clin Pharmacol Ther 2003; 41: 287-93.
138. Ansari F. Use of systemic anti -infective agents in Iran during 1997 -1998. Eur J Clin Pharmacol 2001; 57: 547-51.
139. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55-61.
140. Jirón M, Machado M, Ruiz I. Consumo de antidepresivos en Chile entre 1992 y 2004. Rev Med Chile 2008; 136: 1147-54.
141. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacology. Introduction to Drug Utilization Research. Geneva: World Health Organization, 2003.
142. Coenen S, Ferech M, Haaijer -Ruskamp FM, Butler CC, Stichele RHV, Verheij TJM, et al. European Surveillance of Antimicrobial Consumption: quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care 2007; 16: 440-5.
143. Stanulovic M, Milosev M, Jakovlojevic V, Roncevic N. Epidemiological evaluation of anti -infective drug prescribing for children in outpatient practice. Dev Pharmacol Ther 1987; 10: 278-91.
144. Bergman U, Sjöqvist F. Measurement of drug utilization in Sweden: methodological and clinical implications. Acta Med Scand 1984; 105 (Suppl 683): 15-22.
145. Bergman U. Utilization of antidiabetic drugs in the island of Gotland, Sweden: Agreement between wholesale figures and prescription data. Eur J Clin Pharmacol 1978; 14: 213-20.
146. Bergman U, Dahlström M. Användningen av blodtryckssänkande l äkemedel i Sverige. (Use of antihypertensive agents in Sweden) In: Berglund G, ed. Hypertoni 87. Mölndal: Lindgren and S öner, 1988, pp. 22-32.
147. Bergman U, Dahlström M. Benzodiazepine utilization in Sweden and other Nordic countries. In: Lader MH, Davies HC, eds. Drug Treatment of Neurotic Disorders. Edinburgh: Churchill Livingstone, 1986, pp. 43-52.
148. Juergens JP, Bergman U, Baum C, Kennedy DL, Dahlstrom M. Use of benzodiazepines in the USA and Sweden. Drug Information Association Annual Meeting, Washington, D.C., June 4, 1986.
149. Isacsson G, Holmberg P, Druid H, Bergman U. The utilization of antidepressants -a key issue in the prevention of suicide. An analysis of 5281 suicides in Sweden 1992 -1994. Acta Psychiatr Scand 1997; 96: 94-100.
150. Rönning M, Salvesen Blix H, Harbo BT, Strom H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose-are drug utilization data comparable? Eur J Clin Pharmacol 2000; 56: 723-7.
151. Departamento de Farmacoterapia. Lista Oficial de Medicamentos. Costa Rica: Caja Costarricense de Seguro Social, 2002.
152. The National Essential Drugs Committee. Standard Treatment Guidelines and Essential Drugs List for Primary Health Care, 2nd edn. Pretoria, South Africa: National Department of Health, 1998.
153. Sameerah SAR, Lian LM, eds. Malaysian Statistics on Medicines 2006. Pharmaceutical Services Division and the Clinical Research Centre, Ministry of Health Malaysia, 2006.
154. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994; 10: 405-11.
155. Anonymous. Appendix IV: VA medication classification system. In: USP Dispensing Information, Vol. I: Drug information for the health care professional. Englewood, CO: Micromedex, Inc., 1999, pp. 3045-62.
156. Avorn J, Soumerai SB. Improving drug -therapy decisions through educational outreach: A randomized controlled trial of academically based "detailing." N Engl J Med 1983; 308: 1457-63.
157. Schaffner W, Ray WA, Federspiel CF, Miller WO. Improving antibiotic prescribing in office practice. A controlled trial of three educational methods. JAMA 1983; 250: 1728-32.
158. Ray WA, Schaffner W, Federspiel CF. Persistence of improvement in antibiotic prescribing in office practice. JAMA 1985; 253: 1774-6.
159. Morse ML, LeRoy AA, Gaylord TA, Kellenberger T. Reducing drug therapy -induced hospitalization: impact of drug utilization review. Drug Inf J 1982; 16: 199-202.
160. Groves R. Therapeutic drug -use review for the Florida Medicaid program. Am J Hosp Pharm 1985; 42: 316-9.
161. Hennessy SM, Bilker WB, Zhou L, Weber AL, Brensinger C, Wang Y, Strom BL. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA 2003; 290: 1494-9.
162. Kidder D, Bae J. Evaluation results from prospective drug utilization review: Medicaid demonstrations. Health Care Financ Rev 1999; 20: 107-18.
163. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991 -2000: trend analysis. BMJ 2003; 326: 1008-12.
164. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. N Engl J Med 1987; 317: 550-6.
165. O'Connell DL, Henry D, Tomlins. Randomised controlled trial of feedback on general practitioners prescribing in Australia. BMJ 1999; 318: 507-11.
166. Söndergaard J, Andersen M, Stövring H, Kragstrup J. Mailed prescriber feedback in addition to a clinical guideline has no impact: a randomized, controlled trial. Scand J Prim Health Care 2003; 21: 47-51.
167. Monane M, Mathias DM, Nagle BA, Kelly MA. Improving prescribing patterns for the elderly through an online -drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA 1998; 280: 1249-52.
168. Taylor LK, Tamblyn R. Reasons for physician non -adherence to electronic drug alerts. Stud Health Technol Inform 2004; 107: 1101-5.
169. Anderson GM, Spitzer WO, Weinstein MC, Wang E, Blackburn JL, Bergman U. Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options. Clin Pharmacol Ther 1990; 48: 111-9.
170. Schiff GD, Rucker TD. Computerized prescribing: building the electronic infrastructure for better usage. JAMA 1998; 279: 1024-9.
171. Von Ferber C. Confidentiality Working Group questionnaire. EURO DURG Bull 1998; 3: 3-4.
172. International Society of Pharmacoepidemiology (ISPE). Guidelines for Good Practice in Data Privacy, Medical Record Confidentiality, and Research in the Interest of Public Health. http://www.pharmacoepi.org/ resources/privacy.cfm (accessed June 2011).
173. Lewis MA. ISPE: present, past and future. PharmacoEpidemiology Newsletter 1997; 11: 4.
174. Guess HA, Goldsmith C, Henry D, Strom BL. Pharmacoepidemiology as a focus for clinical epidemiology in developing countries. J Clin Epidemiol 1991; 44 (Suppl): 101-5S.
175. Haaijer -Ruskamp FM, Bergman U. Rational drug use in Europe -challenges for the 21st century. Report from the 1st meeting of EURO DURG, the European Drug Utilization Research Group. Eur J Clin Pharmacol 1997; 52 (Suppl 2): I-VIII.
176. Buschiazzo H, Chaves A, Figueras A, Laporte J-R. Drug utilization in Latin America -the example of DURG-LA. Essential Drugs Monitor 2003; 32: 17-8.
177. Ross-Degnan D, Laing R, Quick J, Ali HM, Ofori-Adjei D, Salako L, et al. A strategy for promoting improved pharmaceutical use: the International Network for Rational Use of Drugs. Soc Sci Med 1992; 35: 1329-41.
178. Lee D. The International Network for Rational Use of Drugs. Essential Drugs Monitor 1997; 24: 7-8.
179. Dartnell JGA. Understanding, Influencing and Evaluating Drug Use. Melbourne, Australia: Therapeutic Guidelines Limited, 2001.
180. Rowe AK, Rowe SY, Vujicic M, Ross-Degnan D, Chalker J, Holloway KA, Peters DH. Review of strategies to improve health care provider performance. In: Peters DH, El-Saharty S, Siadat B, Janovsky K, Vujicic M, eds. Improving Health Service Delivery in Developing Countries: from Evidence to Action. Washington, DC: World Bank, 2009, pp. 101-26.